ARA-290 (Cibinetide): what the human research actually shows
ARA-290 is the rare case where a peptide actually has small Phase 2 RCTs in a real neurological indication. The honest reading is “interesting early human signal, sponsor transitions slowed the program, Phase 3 never delivered.” That is not hype, and it is not nothing.
Why I looked into this
ARA-290 sits in an odd corner of the peptide landscape. Unlike most compounds I write about, it has actual randomized controlled trial data in humans, published in peer-reviewed journals, for real neurological indications. But unlike the GLP-1 drugs, it never crossed the Phase 3 finish line into an approval. The sponsor changed hands multiple times. Program funding moved around. And the internet writeups do not really capture any of that.
I wanted to go back to the actual trial papers, figure out what the Phase 2 results really showed, and understand why a compound with real RCT data for painful diabetic neuropathy and sarcoidosis small-fiber neuropathy is still sitting in the research-use-only market in 2026.
What ARA-290 actually is
ARA-290, also called Cibinetide, is an 11-amino-acid synthetic peptide whose sequence was derived from the aqueous-face exposed residues of the B-helix of erythropoietin. Michael Brines and Anthony Cerami’s group at the Araim Pharmaceuticals-adjacent research program designed it specifically to isolate erythropoietin’s tissue-protective signaling from its hematopoietic signaling.
Classical EPO binds a homodimer of the EPO receptor on red-blood-cell precursors and drives erythropoiesis. EPO’s tissue-protective and anti-inflammatory effects run through a different receptor, the innate repair receptor, which is a heteromer of EPOR and the beta common receptor CD131. ARA-290 preferentially engages the innate repair receptor without meaningfully activating the classical homodimeric EPO receptor, which is why it does not raise red blood cell count. That design separation is the whole point of the molecule. The compound was advanced into clinical work through Araim Pharmaceuticals, then transitioned to Inception 4 Therapeutics, then to EnvyB Therapeutics, with some development gaps between hand-offs.
What the human research shows
Do published human trials exist?
Yes. There are small double-blind, placebo-controlled randomized trials in the published literature, primarily in painful diabetic neuropathy and in sarcoidosis-related small-fiber neuropathy.
This is meaningfully different from the “anecdote plus rodent data” evidence base you see for most peptides. The ARA-290 program ran actual Phase 2 trials, with placebo arms, with validated endpoints, and published the results. The honest caveat is that the trial sizes are small and the Phase 3 step has not been delivered.
What evidence actually exists?
The primary published human evidence is:
- Dahan A et al. Molecular Medicine, 2013. A small double-blind placebo-controlled RCT of ARA-290 in patients with sarcoidosis and small-fiber neuropathy symptoms (n around 22), reporting improvement in neuropathic symptom scales versus placebo.
- Heij L et al. Molecular Medicine, 2012 and 2017. Phase 2 RCT work in painful diabetic peripheral neuropathy (DSPN), 48 patients over 28 days, reporting improvements in corneal nerve fiber density measured by corneal confocal microscopy and in patient-reported pain scores versus placebo.
- Brines M, Dunne AN, van Velzen M, et al. Molecular Medicine, 2014. A broader Phase 2 exploration across neuropathic-pain populations, supporting the painful-neuropathy signal from the 2012 and 2013 papers.
- Subsequent Phase 2b exploration in diabetic neuropathy was conducted, with results published in the peer-reviewed literature.
- Sponsor transitions (Araim to Inception 4 to EnvyB) produced gaps in the clinical program. No successful Phase 3 readout has converted into an FDA approval as of April 2026.
What the research does not show
The research does NOT show:
- Phase 3 efficacy for any indication. All the positive human data is Phase 2 or earlier, and Phase 2 positive results routinely fail to replicate at Phase 3.
- FDA approval for any condition, including the neuropathy indications where the Phase 2 signal exists.
- Benefit outside neuropathy. ARA-290 is sometimes marketed for general anti-inflammatory, recovery, or longevity use. The human RCT evidence is in specific neuropathy populations, not in healthy adults.
- That the absence of hematopoietic effect in short trials means the compound is fully safe at longer timescales or higher exposures. Long-term pharmacovigilance on a non-approved compound does not exist.
- That the compound has a settled commercial future. Multiple sponsor transitions and a stalled Phase 3 path are real, not rumor.
The fair summary is that ARA-290 has the best early-human evidence base of most compounds on this site and still has not made it through the late-stage pipeline that would turn that signal into an approval.
Known safety signals in humans
The published short-term Phase 2 trials generally described ARA-290 as well tolerated, with adverse event rates similar to placebo in the small populations studied. The defining safety feature by design is that the compound does not raise hematocrit, so it avoids the thrombotic risk that limits classical erythropoietin in non-renal-anemia populations. That was confirmed in the trial hemoglobin and hematocrit data.
The honest caveat is that “well tolerated in small Phase 2 trials over weeks to months” is not the same safety story as “well tolerated in thousands of patients over years.” There is no long-term post-market pharmacovigilance record because there is no marketed product. Interaction data with common medications is limited. The safety signals that would appear in a 10,000-patient Phase 3 cohort have not been generated yet.
FDA and legal status in the US
There is no active FDA approval for ARA-290 in the United States. The Phase 2 program produced genuinely positive results in neuropathy indications, but the late-stage pipeline has not converted those results into an approval. Multiple sponsor transitions across Araim, Inception 4, and EnvyB slowed the clinical trajectory. Some trials were stopped for business reasons rather than for safety or futility, which is a different kind of program stall than the Adipotide or AOD-9604 cases.
For a US reader in 2026, ARA-290 is legally an unapproved peptide sold under research-use-only labeling. Compounding-pharmacy access is not established for this compound. The regulatory status could change if a new sponsor runs a successful Phase 3, but as of this writing, nothing in the FDA record changes.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for ARA-290 specifically
The specific source-safety problem with ARA-290 is that it is an 11-amino-acid sequence with a defined structural intent (B-helix mimetic) that research-use-only suppliers rarely verify by mass spectrometry. With an approved reference product, a buyer could cross-check identity; without one, there is no enforced standard. A mis-synthesized or truncated fragment marketed as ARA-290 may have a very different receptor profile than the intended innate-repair-receptor-selective peptide.
The related concern is the EPO family’s shadow. The whole point of ARA-290 is that it does not act like classical EPO. If a substituted or contaminated product does act like classical EPO, the user picks up hematocrit and thrombosis risk that ARA-290 was engineered to avoid. That is a specific, mechanism-aware identity concern, not a generic warning.
Cost reality
Expect a wide range of pricing for material labeled as ARA-290 on the research-use-only market. A licensed 503A compounding pharmacy is unlikely to compound a compound with this kind of development history absent a clinician-led protocol. Most of the supply a user encounters online is not clinical-grade and is not paired with identity verification.
Cost is not a quality signal here. The only reliable signal is independent identity and purity testing by a lab that is not owned by the seller, and most buyers never see that report. For an EPO-family peptide specifically, an identity failure is not a cosmetic-level risk.
Questions worth asking any source
- Are you a licensed 503A compounding pharmacy with a verifiable US state license?
- Do you provide a certificate of analysis from an independent third-party lab, with mass spectrometry confirming the exact 11-amino-acid sequence?
- Do you require a valid prescription from a licensed clinician?
- Do you have a physical US address and a phone number I can verify by calling?
- Can you confirm that the product does not contain full-length erythropoietin or a truncated EPO fragment that would raise hematocrit? What analytical method did you use to rule that out?
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have not used ARA-290. Of the peptides I write about that are not FDA approved, this is the one where the human evidence surprised me most by being actually present. Small Phase 2 RCTs, real placebo arms, real endpoints, published in indexed journals. That is a meaningful step up from the “a Russian research group reported” or “the rodent data looks great” baseline most of the non-approved peptide world runs on.
What keeps ARA-290 from being a recommendation I would feel good about, even outside the medical-advice framing, is the Phase 3 gap. In clinical development, the majority of compounds that look positive at Phase 2 do not survive Phase 3. That is not skepticism, that is the base rate. Without Phase 3, a Phase 2 signal is a hypothesis that has survived one kind of test and has not yet faced the larger, better-powered test that matters most.
The narrower place where I find ARA-290 genuinely interesting is the specific neuropathy population the trials recruited. Small-fiber neuropathy and painful diabetic neuropathy are both clinical problems where the existing options are poor. If a reader has that specific condition, the conversation to have with a neurologist is not “should I try ARA-290 off a research-use-only vendor,” it is “is there a trial I could enroll in or a supervised pathway that would get me a characterized product with oversight.”
For someone who is curious, read Dahan 2013 and the Heij 2017 diabetic neuropathy paper yourself, not the writeups. For someone considering use, ask your neurologist or endocrinologist whether any trial pathway is active, and bring the visit-prep packet. For someone who has already decided to try it, identity verification matters more here than for a generic peptide, because the mechanism is the point.
Questions to ask your doctor
If you are considering ARA-290, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- I have been reading about ARA-290, including Dahan 2013 and Heij 2017 in small-fiber neuropathy and painful diabetic neuropathy. Given that the Phase 2 RCT signal exists but Phase 3 has not delivered, is there a clinical reason to discuss this compound in my situation?
- If I were to consider this compound, what baseline labs and symptom measures would you want to see first, and what would you want to re-check later?
- Given that multiple sponsor transitions have delayed the late-stage program, how would you weigh that in your clinical judgment compared to what is currently marketed online about this compound?
- If the underlying problem is small-fiber neuropathy or painful diabetic neuropathy, what FDA-approved options would you try or rule out first?
- Are there active clinical trials for an erythropoietin-derived neuroprotective peptide in my condition that I could enroll in instead of sourcing material independently?
- Is there any reason to be specifically concerned about the EPO-family origin of this peptide in my particular health profile, such as a clotting history or red-cell-related risk?
What to do next
Read the primary trial papers
Start with Dahan 2013 in Molecular Medicine on sarcoidosis small-fiber neuropathy and Heij 2017 on painful diabetic neuropathy. Read the primary trials, not the writeups.
Open the primer →Ask about a trial pathway
If you have the specific neuropathy this compound was studied in, ask your clinician about active trial enrollment. A supervised trial beats a research-use-only vendor by a wide margin.
Get the packet →Identity verification is mechanism-critical
The whole point of ARA-290 is that it is not classical EPO. An identity failure on this compound turns a safety-by-design peptide into something else. The 503A checklist matters.
Open the checklist →Sources
- Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, Niesters M, Tannemaat MR, Cerami A, Brines M. “ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.” Molecular Medicine. 2013;19:334-345. PMID 24136731.
- Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A. “Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.” Molecular Medicine. 2012;18:1430-1436. PMID 23168581.
- Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A. “ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.” Molecular Medicine. 2014;20:658-666. PMID 25387363.
- Culver DA, Dahan A, Bajorunas D, Jeziorska M, van Velzen M, Aarts LPHJ, Tavee J, Tannemaat MR, Dunne AN, Kirk RI, Petropoulos IN, Cerami A, Malik RA, Brines M. “Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain.” Investigative Ophthalmology and Visual Science. 2017. PMID 28873125.
- Brines M, Cerami A. “The receptor that tames the innate immune response.” Molecular Medicine. 2012;18:486-496. Background review on the innate repair receptor and the rationale for EPO-derived non-hematopoietic peptides. PMID 22183892.
The citation floor here is the Phase 2 RCT literature plus the receptor-biology review. Every efficacy claim in this monograph is tied to a specific published trial.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
BPC-157
The counter-example. Heavy rodent data, zero Phase 2 RCTs. Worth reading next to ARA-290 to see what the gap between “Phase 2 signal” and “animal data only” actually looks like.
GHK-Cu
A different kind of tissue-repair candidate with a different kind of evidence base. Mostly topical and observational. Useful to compare to ARA-290’s trial-based record.
TB-500
Small human Phase 2 data in dry eye and skin ulcers. Another peptide where the real evidence is narrower than the internet pitch. Good to read alongside ARA-290 as a calibration exercise.